# ODTX (Odyssey Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Odyssey Therapeutics, Inc. reported $438.1M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ODTX
- Markdown: https://convexityos.com/fundamentals/ODTX.md
- SEC CIK: 0001882782
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:31 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001882782&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $326.0M | Total debt: $23.48M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | $99K | $959K | $1.92M |
| Research & Development | $42.12M | $36.23M | $32.32M | $26.32M | $30.23M | $38.77M |
| Total Operating Expenses | $56.67M | $55.47M | $39.78M | $38.35M | $42.88M | $41.08M |
| **Operating Income** | -$56.67M | -$55.47M | -$39.78M | -$38.25M | -$41.92M | -$39.16M |
| **EBITDA** | -$55.66M | -$54.43M | -$38.61M | -$37.07M | -$40.65M | -$37.86M |
| Interest Income | $3.86M | $2.83M | $1.71M | $2.20M | $872K | $1.16M |
| Interest Expense | $12K | $20K | $10K | $1.0K | $2.0K | $2.0K |
| Income Before Tax | -$53.01M | -$52.80M | -$38.20M | -$35.52M | -$41.20M | -$38.30M |
| Income Tax Expense | $49K | -$8.0K | $63K | -$56K | $30K | $140K |
| **Net Income** | -$53.06M | -$52.79M | -$38.26M | -$35.46M | -$41.23M | -$38.44M |
| Basic EPS | -$1.10 | -$1.74 | -$6.77 | -$7.78 | -$29.54 | -$39.37 |
| **Diluted EPS** | -$1.10 | -$1.74 | -$6.77 | -$7.78 | -$29.54 | -$39.37 |
| Basic Shares Outstanding | 48.0M | 30.3M | 5.7M | 4.6M | 1.4M | 976.1K |
| Diluted Shares Outstanding | 48.0M | 30.3M | 5.7M | 4.6M | 1.4M | 976.1K |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $80.64M | $82.03M | $35.72M | $41.69M |
| Short-Term Investments | $245.4M | $228.5M | $140.0M | $139.7M |
| **Cash & Short-Term Investments** | $326.0M | $310.6M | $175.7M | $181.4M |
| Accounts Receivable, Net | $0 | $0 | $0 | $0 |
| **Total Current Assets** | $337.8M | $321.5M | $185.1M | $190.7M |
| Property, Plant & Equipment, Net | $4.63M | $4.88M | $6.56M | $7.21M |
| Goodwill | $14.12M | $14.10M | $14.07M | $14.33M |
| Intangible Assets | $0 | $86K | $160K | $262K |
| Long-Term Investments | $60.99M | $122.5M | $0 | $35.20M |
| Other Non-Current Assets | $4.43M | $3.79M | $5.26M | $3.33M |
| **Total Non-Current Assets** | $100.3M | $162.4M | $43.97M | $79.13M |
| **Total Assets** | $438.1M | $483.9M | $229.1M | $269.8M |
| Accounts Payable | $8.26M | $7.67M | $8.22M | $7.87M |
| **Total Current Liabilities** | $26.10M | $28.30M | $22.21M | $26.48M |
| **Total Non-Current Liabilities** | $36.23M | $34.33M | $27.00M | $28.03M |
| **Total Liabilities** | $62.33M | $62.63M | $49.21M | $54.51M |
| **Total Debt (incl. Leases)** | $23.48M | $24.82M | $26.13M | $27.11M |
| Common Stock | $5.0K | $5.0K | $0 | $0 |
| Retained Earnings | -$712.2M | -$659.2M | -$606.4M | -$568.1M |
| Accumulated Other Comp. Income | -$985K | -$505K | -$147K | $245K |
| **Total Stockholders' Equity** | $375.8M | $421.2M | -$523.7M | -$488.3M |
| Total Equity | $375.8M | $421.2M | -$523.7M | -$488.3M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$53.06M | -$52.79M | -$38.26M | -$35.46M | -$41.23M | -$38.44M |
| Depreciation & Amortization | $1.01M | $1.04M | $1.17M | $1.19M | $1.27M | $1.30M |
| Stock-Based Compensation | $7.94M | $5.67M | $2.59M | $4.89M | $3.70M | $2.99M |
| Change in Payables | $651K | -$797K | $484K | -$678K | $278K | $713K |
| **Operating Cash Flow** | -$41.54M | -$34.51M | -$41.03M | -$31.26M | -$34.26M | -$38.62M |
| Capital Expenditure | -$504K | -$186K | -$148K | -$48K | -$29K | -$927K |
| **Free Cash Flow** | -$42.05M | -$34.69M | -$41.18M | -$31.30M | -$34.29M | -$39.55M |
| **Investing Cash Flow** | $43.29M | -$211.4M | $34.80M | -$172.9M | $23.30M | $34.13M |
| **Financing Cash Flow** | -$3.18M | $292.2M | $484K | $90.78M | $118.7M | $200K |
| **Net Change in Cash** | -$1.39M | $46.31M | -$5.72M | -$113.5M | $108.1M | -$4.22M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 12.94x | 11.36x | 8.33x | -- | -- | -- |
| Quick Ratio | 12.49x | 10.98x | 7.91x | -- | -- | -- |
| Debt to Equity | 0.06x | 0.06x | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | -100.0% | -100.0% | -100.0% | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
